尼姆玻利德通过Akt/mTOR通路调节内网膜应激和线粒体功能,从而保护糖尿病心肌病
Haitao Zhang1, Xiaolong Zhao1, Wei Wei2
1Dalian Medical University, Dalian 116044, China.
Tissue & cell
|July 25, 2024
概括
尼姆玻利德通过改善心脏功能和减少心肌损伤,有效治疗糖尿病心肌病 (DCM). 这项研究揭示了它的机制涉及激活Akt/mTOR通路,这表明它有可能成为DCM的新疗法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病心肌病 (DCM) 是糖尿病的一个严重并发症.
- 尼姆玻利德在其他与糖尿病相关的疾病中表现出保护作用,但其在DCM中的作用尚未被探索.
- 了解nimbolide在DCM中的机制对于开发新疗法至关重要.
研究的目的:
- 在体内和体外调查nimbolide对DCM的保护作用.
- 阐明尼姆玻利德在DCM中作用的分子机制.
- 评估nimbolide作为DCM的潜在治疗剂.
主要方法:
- 在使用链毒素 (STZ) 的老鼠中诱导糖尿病;糖尿病老鼠被治疗 nimbolide.
- 在实验室中,H9c2心肌细胞被暴露在高葡萄糖中,以模拟DCM.
- 评估了心脏功能,心肌损伤,内分泌网膜 (ER) 压力,细胞亡,线粒体功能和Akt/mTOR信号传输.
主要成果:
- 尼姆玻利德剂量取决于糖尿病大鼠的血糖降低和体重改善.
- 尼姆玻利德治疗改善了心脏功能,减少了心肌纤维化,ER压力和亡.
- 尼姆玻利德激活了Akt/mTOR通路并改善了线粒体功能,其作用被Akt抑制剂部分阻断.
结论:
- 尼姆玻利德通过改善心脏功能和减轻心肌损伤,在DCM中表现出显著的心脏保护作用.
- 保护机制包括激活Akt/mTOR信号通路和调节ER压力和线粒体功能的调节.
- 尼姆玻利德代表了一种有前途的新型治疗候选药物,用于治疗糖尿病心肌病.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
387
07:14A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation
Published on: July 13, 2018
14.3K
相关概念视频
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
414
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
414
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:26Heart Failure Drugs: Inotropic Agents
559
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
559